vimarsana.com

Latest Breaking News On - Severity index activity - Page 1 : vimarsana.com

Afimetoran Shown to be Safe, Well-Tolerated for Patients with Cutaneous Lupus Erythematosus

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with cutaneous lupus erythematosus (CLE).

California
United-states
San-diego
Fareeda-hosein
Bristol-myers-squibb
American-college-of-rheumatology
American-college
With-lupus-erythematosus
Bristol-myers
Severity-index-activity
Afimetoran
Lupus

Jonathan Sadeh, MD, MSc: Afimetoran Improves Disease Activity, Severity in Lupus

Results provide the first clinical evidence to suggest that afimetoran may offer a benefit to patients with cutaneous lupus erythematosus.

Jonathan-sadeh
Bristol-myers-squibb
American-college-of-rheumatology
Global-program-leaders
Severity-index-activity
American-college

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.